Entering text into the input field will update the search result below

Novo Nordisk backs out of collaboration with Zosano Pharma to develop transdermal GLP-1 analogues

  • In a regulatory filing, Zosano Pharma (NASDAQ:ZSAN) discloses that Novo Nordisk (NYSE:NVO) notified it that it will terminate their January 2014 collaboration to develop transdermal formulations of Novo's glucagon-like peptide (GLP-1) analogues. Novo's decision is based on its desire to focus on other priorities in its research portfolio. Once the agreement ends, all technology rights licensed to Novo will revert back to Zosano.
  • There has been no after hours trading in ZSAN shares yet.

Recommended For You

Related Stocks

SymbolLast Price% Chg
ZSANQ--
Zosano Pharma Corporation